X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs TORRENT PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS TORRENT PHARMA NOVARTIS/
TORRENT PHARMA
 
P/E (TTM) x 329.0 44.3 742.8% View Chart
P/BV x 36.5 6.3 582.9% View Chart
Dividend Yield % 1.3 0.8 153.0%  

Financials

 NOVARTIS   TORRENT PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
TORRENT PHARMA
Mar-18
NOVARTIS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7581,550 48.9%   
Low Rs5791,144 50.6%   
Sales per share (Unadj.) Rs228.4354.7 64.4%  
Earnings per share (Unadj.) Rs31.740.1 79.2%  
Cash flow per share (Unadj.) Rs32.864.2 51.0%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.51.0 143.9%  
Book value per share (Unadj.) Rs297.1273.1 108.8%  
Shares outstanding (eoy) m24.69169.22 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.8 77.1%   
Avg P/E ratio x21.133.6 62.7%  
P/CF ratio (eoy) x20.421.0 97.3%  
Price / Book Value ratio x2.24.9 45.6%  
Dividend payout %31.534.9 90.2%   
Avg Mkt Cap Rs m16,505227,897 7.2%   
No. of employees `0000.714.7 4.5%   
Total wages/salary Rs m1,44511,353 12.7%   
Avg. sales/employee Rs Th8,441.34,083.0 206.7%   
Avg. wages/employee Rs Th2,163.6772.3 280.2%   
Avg. net profit/employee Rs Th1,173.1461.3 254.3%   
INCOME DATA
Net Sales Rs m5,63960,021 9.4%  
Other income Rs m1,7182,988 57.5%   
Total revenues Rs m7,35763,009 11.7%   
Gross profit Rs m-6313,493 -0.5%  
Depreciation Rs m254,086 0.6%   
Interest Rs m553,085 1.8%   
Profit before tax Rs m1,5759,310 16.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,529 31.3%   
Profit after tax Rs m7846,781 11.6%  
Gross profit margin %-1.122.5 -4.9%  
Effective tax rate %50.327.2 185.0%   
Net profit margin %13.911.3 123.0%  
BALANCE SHEET DATA
Current assets Rs m9,52252,623 18.1%   
Current liabilities Rs m3,29652,022 6.3%   
Net working cap to sales %110.41.0 11,016.7%  
Current ratio x2.91.0 285.6%  
Inventory Days Days37120 30.6%  
Debtors Days Days2876 37.3%  
Net fixed assets Rs m4685,016 0.1%   
Share capital Rs m123846 14.6%   
"Free" reserves Rs m7,21345,376 15.9%   
Net worth Rs m7,33646,222 15.9%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m11,105142,432 7.8%  
Interest coverage x29.54.0 733.8%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.50.4 120.5%   
Return on assets %7.66.9 109.1%  
Return on equity %10.714.7 72.8%  
Return on capital %22.214.2 156.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6114,580 0.4%   
Fx outflow Rs m3,6303,600 100.8%   
Net fx Rs m-3,57010,980 -32.5%   
CASH FLOW
From Operations Rs m1,6108,942 18.0%  
From Investments Rs m687-47,070 -1.5%  
From Financial Activity Rs m-2,67734,174 -7.8%  
Net Cashflow Rs m-380-3,655 10.4%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 7.0 28.5%  
FIIs % 1.6 12.6 12.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.8 244.3%  
Shareholders   41,647 26,511 157.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  ASTRAZENECA PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 26, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS